Diabetic Nephropathy Market was valued USD 2.48 billion in 2021 and is expected to reach USD 3.43 billion by 2030 at 6.20% CAGR during the forecast period 2022-2030. Diabetes is when the pancreas isn't working correctly, and the blood sugar level is abnormally high. Nephropathy is a term for kidney dysfunction or disease. One of the main consequences for the diabetic population in terms of morbidity and mortality in diabetic nephropathy is kidney glomerulus disease. The early stages of diabetic nephropathy have no documented symptoms. However, key indications and symptoms, including high blood pressure, ankle and leg edema, vomiting, morning weakness, high blood urea nitrogen levels, increased albumin excretion in urine, nausea, and itching, only appear in the later stages.
Some key factors propelling the worldwide diabetic nephropathy market include a growth in the incidence of diabetes and obesity, increased research and development expenditures for medication discovery and development, and increased awareness of illnesses associated with diabetes and the kidneys. On the other hand, the market's expansion is constrained by strict regulatory requirements, a protracted medication approval process, a lack of comprehensive therapeutic care for diabetic nephropathy, and these factors combined. On the other hand, the market for treating diabetic nephropathy is seeing a growth in the popularity of combination therapy. This is related to the rising frequency of renal disorders and the growth in the number of people with diabetes, which are predicted to present the profitable potential for market expansion. The industry is fiercely competitive, and the leading competitors concentrate on raising awareness of diabetic nephropathy.
COVID 19 Analysis:
The Diabetic Nephropathy condition was increasing in the countries like the United States since the isolation imposed due to the pandemic has increased the severity of diabetic patients. As the grocery stores were closed or people remained home have started consuming unhealthy diet, especially not suitable for people with Diabetic Nephropathy condition. A study states that more than 40% of people who died of COVID had diabetes. The inaccessibility of healthy food options and places like gyms or jogging tracks has worsened the condition.
The disruption in the supply chain and reduction in the production units have limited the raw materials required to manufacture the diabetes monitoring devices. This factor has also impacted the Diabetic Nephropathy industry during the pandemic.
The increasing chronic diseases such as obesity, diabetes, and other chronic illness have increased the demand for diagnostic tests like urine tests, blood tests, tests related to kidney functioning, and imaging tests like MRI and CT scans. The mortality rate has increased to 59% and the number of deaths has increased to 35 million in the year 2019. These factors are driving the Diabetic Nephropathy market growth in recent years.
The recent treatments of administrating drugs like Spironolactone followed by Eplerenone for the patients with mild or moderate arterial hypertension and albuminuria. The recent approval for novel drugs like finerenone has a significant impact on the glomerular filtration rate. Such factors have promoted the growth of the Diabetic Nephropathy industry.
The surging success rates in disease-modifying therapies that include the drugs like Angiotensin II receptor blockers and Angiotensin-converting enzyme inhibitors have created a huge impact on the growth of the Diabetic Nephropathy market value. Additionally, the superior protection offered by the ACE inhibitors and ARB inhibitors has increased the life of the failing kidneys of the patients when administrated. Such factors have increased the demand for the Diabetic Nephropathy industry.
The increasing investment in the Diabetic Nephropathy market by the leading players to improve the services has fueled the overall growth of the Diabetic Nephropathy market value. The increasing investments have significantly increased the R&D development for drug discovery, research works, and treatments for kidney-related disorders in recent years. These showed up significant performance in the global market in recent years. Additionally, these factors are expected to stimulate the growth of the Diabetic Nephropathy industry.
Several countries have imposed stringent regulations over the drugs administrated for Diabetic Nephropathy. For instance, Captopril is the only drug among the other ACE inhibitors that have gotten FDA approval. Considering the interactions of the ACE inhibitors, the approval for them has always been difficult. This factor is considered as the primary restraint in the Diabetic Nephropathy market growth.
The strict recommendation to avoid ACE inhibitors during pregnancy and lactation has restricted the growth of the Diabetic Nephropathy market value. The corresponding alternative that provides minimal drug reactions is expected by the market players.
Lack of skilled professionals in the regions where the cases are surging is considered as the primary restraining factor of the Diabetic Nephropathy market growth. The emerging treatments that offer promising results are to be administered with the well-equipped and controlled method. Understanding the aspects associated with the novel drugs requires skilled professionals in Diabetic Nephropathy.
The Oral administration of Spironolactone followed by Eplerenone has controlled the condition in a promising manner, however has created the risk of the development of hyperkalemia is suppressing. Since the combination of inhibitors is administrated in the treatments, the risks of renal failure are predominantly noticed when the ACE inhibitors are combined with ARBs. Adverse effects like diarrhea, hypotension, syncope, and hyperkalemia have been noted in such cases. These adverse effects of drugs have restricted the growth of the Diabetic Nephropathy industry.
Cumulative growth analysis:
Diabetic Nephropathy treatment requires way more development. Incomplete therapeutic management and stringent regulations by the medical associations and federations have significantly hindered the growth of the Diabetic Nephropathy market growth in recent years. Additionally, despite series of research efforts, the market still lacks novel strategies and treatment to prevent or arrest the condition once encountered. In addition to that, the increasing fatality rates have imposed a significant effect on the growth of the Diabetic Nephropathy industry.
The new launches in the Diabetic Nephropathy market have created a significant impact on the growth. The understanding of the condition has increased tremendously in recent years and therefore personalized treatments and drugs are administrated to the patients which have shown a decent success rate. The improvement in renal and cardiovascular protection in diabetic patients has improved with intensive care and personalized prescription. However, the surging number of diabetic cases and increasing awareness regarding the condition has increased the Diabetic Nephropathy market growth.
Value chain analysis:
Over 40% of patients with diabetes mellitus possess diabetic nephropathy where the kidney is constantly exposed to hyperglycemia. Diabetes has become common in several countries for the sedentary lifestyle, habits like alcohol consumption, improper diet, and genetics. There were over 26 million people in the United States who were reported diabetics, of which 200,000 patients were either on chronic renal dialysis or kidney transplant. These factors have impacted the growth of the Diabetic Nephropathy market across the globe.
The major side effects of chronic diabetic nephropathy are progressive growth in proteinuria, renal failure, hypertension, higher risks of cardiovascular disease.
Based on diagnosis:
Based on treatment:
Angiotensin-converting enzyme inhibitors angiotensin II receptor blockers
Antioxidant inflammation modulators, renin inhibitors
Calcium channel blockers
Connective tissue growth factor inhibitors
Monocyte chemoattractant proteins inhibitor
Endothelin-A receptor antagonist
Based on indication:
The Diabetic Nephropathy market share of America is currently considered the largest among other countries in the world. Extensive use of diagnostic tests, continuous monitoring, and higher blood pressure rates in the patients are some of the major driving factors of the Diabetic Nephropathy market growth. Additionally, the other kidney-related complaints prevalently found in the region, over 15% of adults in the country is expected to have any one of the chronic kidney diseases which has also impacted the growth of the Diabetic Nephropathy industry in the United States.
On the other hand, the European market is driven by diagnostic services and home diagnosis services. The emerging-market players in the manufacturers of medical devices have boosted the growth of the Diabetic Nephropathy industry in the region. Additionally, Asia-pacific is currently witnessing a higher number of cases related to chronic diseases like obesity, diabetes, cardiac arrests.
This report has covered:
|Market Size||USD 3.43 Billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment, Indication and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Merck & Co., Inc. (U.S.), Bayer AG (Germany), Abbott (U.S.), Sanofi (France), Novartis AG (Switzerland), Reata Pharmaceuticals, Inc. (U.S.), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Eli Lilly and Company (U.S.), General Electric Company (U.S.), Siemens AG (Germany), Mitsubishi Tanabe Pharma Corporation (Japan)|
|Key Market Opportunities||Technological advancements in diagnostic imaging|
|Key Market Drivers||
Diabetic Nephropathy is a side effect of diabetes and is caused by the presence of high amounts of glucose in the blood, which makes the filters in the kidney porous and leaky.
The market is expected to exhibit a strong 6.20% CAGR over the forecast period from 2022 to 2030.
Leading players in the Diabetic Nephropathy Market include Merck, Bayer, and Abbott, among others.The growing prevalence of diabetes is the major driver for the market.
The Americas dominated the global Diabetic Nephropathy Market in 2016.
The growing prevalence of diabetes is the major driver for the market.